Announcement • May 07
PLAYSTUDIOS Transfers Listing Of Common Stock And Warrants From Nasdaq Global Market To Nasdaq Capital Market Effective May 6, 2026
As previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission on November 10, 2025, on November 5, 2025, PLAYSTUDIOS, Inc., a Delaware corporation, received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1), as the closing bid price for the Company's Class A common stock, par value $0.0001 per share, had been below $1.00 per share for 30 consecutive business days. The notice had no immediate effect on the listing of the Company's securities, and the Common Stock continued to trade on the Nasdaq Global Market under the symbol MYPS. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial 180 calendar day compliance period, expiring on May 4, 2026, to regain compliance with the Minimum Bid Price Requirement. To regain compliance during the First Compliance Period, the closing bid price of the Common Stock was required to be at least $1.00 per share for a minimum of ten consecutive business days, which did not occur. On April 7, 2026, the Company submitted to Nasdaq an application to transfer the listing of its Listed Securities from the Nasdaq Global Market to the Nasdaq Capital Market, as permitted under Nasdaq Listing Rule 5810(c)(3)(A)(ii), and requested an additional 180 calendar day period to regain compliance with the Minimum Bid Price Requirement. On May 5, 2026, Nasdaq staff approved the Company's application to transfer its listing to the Nasdaq Capital Market. The transfer will become effective at the opening of business on May 6, 2026 and will have no immediate effect on the trading of the Listed Securities, which will continue to trade under the symbol MYPS. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, and issuers listed on the Nasdaq Capital Market must continue to meet specified financial and corporate governance requirements. As a result of the transfer, Nasdaq granted the Company a second 180 calendar day compliance period, expiring November 2, 2026, to regain compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2). To regain compliance, the closing bid price of the Common Stock must be at least $1.00 per share for a minimum of ten consecutive business days on or prior to November 2, 2026. If the Company chooses to implement a reverse stock split in order to cure the deficiency, the split must be completed no later than ten business days prior to the expiration of the Second Compliance Period to allow time for Nasdaq verification of compliance. Nasdaq's determination to grant the additional compliance period was based on, among other factors, (i) the Company's satisfaction of the market value of publicly held shares standard and all other applicable initial listing requirements for the Nasdaq Capital Market (except for the Minimum Bid Price Requirement), (ii) the Company's written notice of its intention to cure the deficiency by effecting a reverse stock split if necessary, (iii) its agreement to the conditions under the Nasdaq listing agreement, and (iv) the additional supporting information provided with its application. If at any time during the Second Compliance Period the closing bid price of the Common Stock is at least $1.00 per share for a minimum of ten consecutive business days, Nasdaq will provide written confirmation to the Company and the matter will be closed. If the Company does not regain compliance by November 2, 2026, or fails to satisfy the terms of the extension, Nasdaq staff will issue a notice that the Company's securities are subject to delisting, which the Company may appeal to a Nasdaq Hearings Panel; however, there can be no assurance that any such appeal would be successful. The Company will continue to monitor the closing bid price of its Common Stock and, as appropriate, will consider available options to cure the deficiency and regain compliance, including by effecting a reverse stock split, if necessary, prior to the expiration of the Second Compliance Period.
